- Home
- NWAX vs FENC Comparison
NWAX vs FENC Comparison
Compare NWAX & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$12.47
Company Overview
Basic Information| Metric | NWAX | FENC |
|---|---|---|
| Founded | 2025 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.0M | 430.3M |
| IPO Year | 2025 | 2010 |
Fundamental Metrics
Financial Performance| Metric | NWAX | FENC |
|---|---|---|
| Price | $10.14 | $12.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 106.4K | ★ 262.7K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ N/A | $206.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.68 | $5.65 |
| 52 Week High | $10.34 | $13.25 |
Technical Indicators
Market Signals| Indicator | NWAX | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 42.49 | 60.00 |
| Support Level | $10.06 | $9.74 |
| Resistance Level | $10.16 | N/A |
| Average True Range (ATR) | 0.02 | 0.59 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 14.29 | 81.15 |
Price Performance
Historical Comparison NWAX
FENC
About NWAX New America Acquisition I Corp. Class A Common Stock
New America Acquisition I Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which it refers to throughout this prospectus as its initial Business Combination.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.